Abstract:Amenamevir (ASP2151), a novel, non‐nucleoside analog, antiviral drug, inhibits the enzyme activities of helicase and primase, which are essential for replication of herpes viral genomic DNA. In this phase 3, randomized, double‐blind, placebo‐controlled, multicenter study, the authors investigated the efficacy and safety of a single patient‐initiated dose of amenamevir to treat recurrent herpes labialis. Adult immunocompetent patients with recurrent herpes labialis who had the experience and ability to recogniz… Show more
“…Amenamevir also suppresses the acyclovir‐resistant strain of HSV and VZV 53 . Amenamevir is currently available and labeled only for herpes zoster in Japan but is now being developed for the treatment of herpes simplex 54,55 . The efficacy and safety of amenamevir against HSV have already been confirmed in two independent clinical trials for oral 54 and genital 55 herpes, respectively, with patient‐initiated therapy format.…”
Section: Treatment Of Herpes Simplexmentioning
confidence: 99%
“…Amenamevir is currently available and labeled only for herpes zoster in Japan but is now being developed for the treatment of herpes simplex 54,55 . The efficacy and safety of amenamevir against HSV have already been confirmed in two independent clinical trials for oral 54 and genital 55 herpes, respectively, with patient‐initiated therapy format. The dosage and administration of amenamevir is 1200 mg only once, which should contribute to improved compliance.…”
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
“…Amenamevir also suppresses the acyclovir‐resistant strain of HSV and VZV 53 . Amenamevir is currently available and labeled only for herpes zoster in Japan but is now being developed for the treatment of herpes simplex 54,55 . The efficacy and safety of amenamevir against HSV have already been confirmed in two independent clinical trials for oral 54 and genital 55 herpes, respectively, with patient‐initiated therapy format.…”
Section: Treatment Of Herpes Simplexmentioning
confidence: 99%
“…Amenamevir is currently available and labeled only for herpes zoster in Japan but is now being developed for the treatment of herpes simplex 54,55 . The efficacy and safety of amenamevir against HSV have already been confirmed in two independent clinical trials for oral 54 and genital 55 herpes, respectively, with patient‐initiated therapy format. The dosage and administration of amenamevir is 1200 mg only once, which should contribute to improved compliance.…”
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.